Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
Executive Summary
Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.
You may also be interested in...
Europe Biotech Heavyweights Genmab And Argenx Ink Antibody Alliance
The two flagship firms of the European biotech scene are pooling their technologies to jointly discover, develop and commercialize drugs against cancer and autoimmune diseases.
Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.